Tom Cavanaugh: Inspired by the topline results from the Phase 3 MARIPOSA study
Biljana Naumovic, President of US Oncology at Johnson and Johnson Innovative Medicine, about a recent article published in JNJ:
“I am inspired by the Johnson and Johnson Innovative Medicine team in Oncology and topline results from the Phase 3 MARIPOSA study. The trial shows an overall survival benefit versus the current standard of care in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
At Johnson and Johnson, we envision a world in which cancer is eliminated and remain steadfast in our commitment to making a positive impact on the lives of those affected by NSCLC.
I am proud of our team and strong start to 2025 as we deepen our dedication to delivering for patients and leading where medicine is going.
Read more about this milestone in lung cancer treatment.”
Quoting Biljana Naumovic’s post:
“When we talk about lung cancer, we’re not just talking about statistics. We’re talking about lives—about parents, siblings, friends, and loved ones fighting an uphill battle every single day. Behind every number is a story, a family, and a hope for a better tomorrow.
Today, that hope feels a little brighter. The results from the Phase 3 MARIPOSA study mark a pivotal moment in the fight against EGFR-mutated non-small cell lung cancer.
For the first time, we’re seeing an overall survival benefit over the current standard of care — an achievement that could mean more time, more milestones, and more moments for so many patients.
This progress didn’t happen by chance. It’s the result of tireless dedication from the Johnson and Johnson Innovative Medicine team. To all who contributed to this breakthrough: you’ve made a difference, and I couldn’t be prouder.
As we step into 2025, let’s carry this momentum forward. Let’s stay relentless in our mission to transform outcomes for patients and families living with lung cancer. Because when we come together—when we innovate and persevere — we move closer to a future where hope prevails.
I encourage you to read about it.”
Proceed to the video attached to the post.
More posts featuring Biljana Naumovic
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023